Investor Area

News

Announcements by type

  • Presentation

  • Corporate

  • Newsletter

  • Regulatory

  • Financial

  • Clinical

  • Reset

 

CLINUVEL PHARMACEUTICALS LTD today informed its shareholders and interested investors that Jefferies Australia Pty Ltd has initiated independent analyst coverage on the Company. […] Download PDF

Download PDF
 
 

The Value in the Vines Investor Conference Presentation is available to download.

Download PDF
 
 

  Appendix 4G and Corporate Governance Statement is available to download.

Download PDF
 
 
Friday, 09 October 2020

CLINUVEL Annual Report 2020

CLINUVEL’s Annual Report for the year ended 30 June 2020 is available to download here.

Download PDF
 
 
Friday, 09 October 2020

CLINUVEL Annual General Meeting 2020

CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on Wednesday, 11 November 2020 at 06.00pm (Melbourne time). To comply with COVID19 requirements set out in Government restrictions on travel and public gatherings, the AGM will be held as a virtual meeting. The Company will rely on technology to facilitate shareholder engagement during […]

Download PDF
 
 
Wednesday, 07 October 2020

SCIENTIFIC COMMUNIQUÉ VI

Despite government campaigns to curb increases, current statistics show the rate of skin cancer is escalating, particularly in regions with predominantly fair-skinned populations. Skin cancer diagnoses have increased considerably over the last five decades, at a rate of 4% per annum. Approximately 5.3 million individuals are diagnosed with a skin cancer in the USA annually. […]

Download PDF
 
 
Tuesday, 06 October 2020

CLINUVEL News & Facts site live

Earlier this week CLINUVEL launched a new microsite, CLINUVEL News & Facts. The CLINUVEL News & Facts site gives an opportunity to explore and discuss the people, science and ideas that underpin CLINUVEL. Read more about the concept here.

Download PDF
 
 
Monday, 28 September 2020

Kommuniqué V, 2020

Kommuniqué V, 2020

Download PDF
 
 
Wednesday, 23 September 2020

CLINUVEL Newsletter V

CLINUVEL Newsletter V, 2020

Download PDF
 
 
Wednesday, 23 September 2020

CLINUVEL Confirms AGM Date

CLINUVEL Confirms AGM Date

Download PDF
 
 
Wednesday, 16 September 2020

Change of Director’s Interest Notice

Appendix 3Y – Change of Director’s Interest Notice is available to download as PDF

Download PDF
 
 

First patient dosed in SCENESSE® DNA Repair Program Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment In the search for a preventative treatment of skin cancers, including melanoma, it is imperative to understand and treat DNA damage caused by ultraviolet (UV) radiation. Following the treatment of a patient suffering from xeroderma pigmentosum (XP), a disease characterised […]

www.clinuvel.com.

Download PDF

 
 

Xeroderma pigmentosum (XP) patient receives SCENESSE® treatment CLINUVEL PHARMACEUTICALS LTD today announced that the first patient diagnosed with xeroderma pigmentosum (XP-C) has received SCENESSE® (afamelanotide 16mg).1 The Special Access Program of one patient is part of CLINUVEL’s DNA Repair Program. CLINUVEL is evaluating SCENESSE® in a staged clinical program to confirm the drug’s ability to […]

www.clinuvel.com.

Download PDF

 
 

Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with SCENESSE® causes elimination of DNA damage (photoproducts) and regeneration of DNA. The diagram shows that SCENESSE® has been proven to protect skin from light (photoprotection) and shown to repair DNA damage. Since photoprotection and regeneration are necessary to reduce the risk of skin […]

www.clinuvel.com.

Download PDF

 
 

CLINUVEL progresses innovative DNA Repair Program Drug tested to protect skin and regenerate DNA, firstly in XP patients at 10,000-fold skin cancer risk Figure 1: CLINUVEL’s DNA Repair Program aims to confirm that intervention with SCENESSE® causes elimination of DNA damage (photoproducts) and regeneration of DNA. The diagram shows that SCENESSE® has been proven to […]

www.clinuvel.com.

Download PDF

 

Dearest Shareholders, As the incoming Chair of the Company, in short letters I will try to provide you with updates and inform you about our business.[...]

Download PDF
 

 CLINUVEL PHARMACEUTICALS LTD today announced that Mr Stan McLiesh will retire from his role as Non-Executive Director and Chair of the Board on 30 November 2019. Non-Executive Director Mr Willem Blijdorp has been elected Chair …

Download PDF
 
Thursday, 17 October 2019

CLINUVEL Newsletter

  In this News Communiqué VII, we pause to reflect on the outstanding US regulatory outcome and look back one last time at all the events which led to the long-desired outcome on 8 October, the …

Download PDF
 
Tuesday, 15 October 2019

Chair Letter to Shareholders

  Dear All, In my career in life sciences, I have served on public Boards, was part of the management team that led CSL to its position and oversaw several executive transitions in our beloved Company, first …

Download PDF
 
Tuesday, 20 August 2019

CLINUVEL Newsletter - August 2019

  Dear patients, shareholders, friends, In this News Communiqué VI for the year we report further on CLINUVEL’s regulatory progress in the US and the latest quarterly results for the period ending 30 June 2019. [...]

Download PDF
 
Thursday, 11 July 2019

CLINUVEL Newsletter - July 2019

  In this Communiqué we turn our attention to the most recent news communicated to the Company on 31 May by the US Food and Drug Administration (FDA): an extension of the scientific review time for …

Download PDF
 
Thursday, 02 May 2019

CLINUVEL Newsletter

02 May 2019  Dear patients, shareholders, friends,In this Communiqué we concentrate on CLINUVEL’s programs and US market access for SCENESSE®.As the European season unfolds, we report on the back of quarterly financials (released 30 April) …

Download PDF
 
Wednesday, 24 April 2019

Chair Letter to Shareholders

24 April 2019   Dear All,On a continent where very few biotechnology and pharmaceutical companies have ever succeeded in taking a first-in-class and first-in-line therapy from concept to commercialisation, CLINUVEL has all the makings of becoming …

Download PDF
 
Wednesday, 20 March 2019

CLINUVEL Newsletter – March 2019

20 March 2019  Dear patients, shareholders, friends,In the third Communiqué we are reviewing our EU operations, the impact of Brexit and looking at the year ahead. FDA REVIEWAt the time of print CLINUVEL will find itself …

Download PDF
 
Tuesday, 12 February 2019

CLINUVEL Vitiligo Communiqué II

12 February 2019   In the second Communiqué we look closer at the role of narrowband UVB (NB-UVB) as the only standard of care at present in vitiligo, both the segmental and generalised form of the disease. …

Download PDF